

# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

# PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

(PCT Rule 44.1)

To:

**D YOUNG & CO**  
Attn. Mallalieu, Catherine L.  
21 New Fetter Lane  
London EC4A 1DA  
UNITED KINGDOM

Date of mailing  
(day/month/year)

09/05/2003

Applicant's or agent's file reference

**P011069WO CLM**

**FOR FURTHER ACTION**

See paragraphs 1 and 4 below

International application No.

**PCT/GB 02/ 03381**

International filing date  
(day/month/year)

25/07/2002

Applicant

**LORANTIS LIMITED**

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

**For more detailed instructions,** see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90b/s.1 and 90b/s.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Stefanie Bichler

*Stefanie Bichler*

## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

**The amendments must be made in the language in which the international application is to be published.**

#### What documents must/may accompany the amendments?

##### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

**The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.**

## NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

**The following examples illustrate the manner in which amendments must be explained in the accompanying letter:**

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### **"Statement under article 19(1)" (Rule 46.4)**

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### **Consequence if a demand for international preliminary examination has already been filed**

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

### **Consequence with regard to translation of the international application for entry into the national phase**

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>P011069W0 CLM</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/GB 02/ 03381</b>	International filing date (day/month/year) <b>25/07/2002</b>	(Earliest) Priority Date (day/month/year) <b>25/07/2001</b>
Applicant  <b>LORANTIS LIMITED</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 13 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

**CONJUGATES FOR THE MODULATION OF IMMUNE RESPONSES**

5. With regard to the **abstract**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

1  
☐ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 02/03381

Box III TEXT OF THE ABSTRACT (Continuation of first sheet)

A conjugate comprising first and second sequence wherein the first sequence comprises a polypeptide which is capable of binding to antigen presenting cell (APC) and the second sequence is a polypeptide comprising a modulator of the Notch signalling pathway.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 02/03381

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 35(partly)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
1-35
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

## Inventions 1 (Claims 1-6, 16-18 and 25-35)

A conjugate comprising first and second sequences wherein the first sequence comprises a polypeptide which is capable of binding to an antigen presenting cell (APC) surface molecule MHC class II, or is a polynucleotide which encodes therefor, and a second sequence comprises a polypeptide capable of modulating of a T cell signalling pathway according to claims 2-5, wherein it is Notch or a fragment thereof which retains the signalling transduction ability of Notch or an analogue of Notch which has the signalling transduction ability of Notch or a polynucleotide sequence which encodes therefor, expression vectors comprising corresponding sequences according to claim 26 and the corresponding sequences according to claim 26, hosts according to claim 27, a method of preparing the conjugates according to claim 28, conjugates according to claim 29, methods of targeting a protein for notch signalling modulation according to claim 30, pharmaceutical compositions according to claims 31,32, uses of the conjugates according to claims 33,34, and products according to claim 35, respectively.

## Inventions 2-14 (Claims 1-6, 16-18 and 25-35)

A conjugate comprising first and second sequences wherein the first sequence comprises a polypeptide which is capable of binding to an antigen presenting cell (APC) surface molecule selected from the group consisting of the following 13 further embodiments, in respect to each invention: CD205, CD204, CD14, CD206, TLR, CD207, CD209, Fc gamma receptor, CD68, CD83, CD33, CD54 or BDCA-2,3,4, or is a polynucleotide which encodes therefor, and a second sequence comprises a polypeptide capable of modulating of a T cell signalling pathway according to claims 2-5, wherein it is Notch or a fragment thereof which retains the signalling transduction ability of Notch or an analogue of Notch which has the signalling transduction ability of Notch or a polynucleotide sequence which encodes therefor, expression vectors comprising corresponding sequences according to claim 26 and the corresponding sequences according to claim 26, hosts according to claim 27, a method of preparing the conjugates according to claim 28, conjugates according to claim 29, methods of targeting a protein for notch signalling modulation according to claim 30, pharmaceutical compositions according to claims 31,32, uses of the conjugates according to claims 33,34, and products according to claim 35, respectively.

## Invention 15 (Claims 1-6, 16-24 and 25-35)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A conjugate comprising first and second sequences wherein the first sequence comprises a polypeptide which is capable of binding to an antigen presenting cell (APC) surface molecule wherein the sequence is derived from superantigen according to claims 19-24, or is a polynucleotide which encodes therefor, and a second sequence comprises a polypeptide capable of modulating of a T cell signalling pathway according to claims 2-5, wherein it is Notch or a fragment thereof which retains the signalling transduction ability of Notch or an analogue of Notch which has the signalling transduction ability of Notch or a polynucleotide sequence which encodes therefor, expression vectors comprising corresponding sequences according to claim 26 and the corresponding sequences according to claim 26, hosts according to claim 27, a method of preparing the conjugates according to claim 28, conjugates according to claim 29, methods of targeting a protein for notch signalling modulation according to claim 30, pharmaceutical compositions according to claims 31,32, uses of the conjugates according to claims 33,34, and products according to claim 35, respectively.

## Inventions 16-30 (claims 1-5,7,8,16-18 and 25-35)

A conjugate comprising first and second sequences wherein the first sequence comprises a polypeptide which is capable of binding to an antigen presenting cell (APC) surface molecule selected from the group consisting of the following 14 embodiments, in respect to each invention: MHC class II, CD205, CD204, CD14, CD206, TLR, CD207, CD209, Fc gamma receptor, CD68, CD83, CD33, CD54 or BDCA-2,3,4, or is a polynucleotide which encodes therefor, and a second sequence comprises a polypeptide capable of modulating of a T cell signalling pathway according to claims 2-5, wherein it is Notch ligand or a fragment thereof which retains the signalling transduction ability of Notch ligand or an analogue of Notch ligand which has the signalling transduction ability of Notch ligand or a polynucleotide sequence which encodes therefor, wherein the sequence is derived from Delta or Serrate, expression vectors comprising corresponding sequences according to claim 26 and the corresponding sequences according to claim 26, hosts according to claim 27, a method of preparing the conjugates according to claim 28, conjugates according to claim 29, methods of targeting a protein for notch signalling modulation according to claim 30, pharmaceutical compositions according to claims 31,32, uses of the conjugates according to claims 33,34, and products according to claim 35, respectively.

## Invention 31 (claims 1-5,7,8,16-24 and 25-35)



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A conjugate comprising first and second sequences wherein the first sequence comprises a polypeptide which is capable of binding to an antigen presenting cell (APC) surface molecule wherein the sequence is derived from superantigen according to claims 19-24, or is a polynucleotide which encodes therefor, and a second sequence comprises a polypeptide capable of modulating of a T cell signalling pathway according to claims 2-5, wherein it is Notch ligand or a fragment thereof which retains the signalling transduction ability of Notch ligand or an analogue of Notch ligand which has the signalling transduction ability of Notch ligand or a polynucleotide sequence which encodes therefor, wherein the sequence is derived from Delta or Serrate, expression vectors comprising corresponding sequences according to claim 26 and the corresponding sequences according to claim 26, hosts according to claim 27, a method of preparing the conjugates according to claim 28, conjugates according to claim 29, methods of targeting a protein for notch signalling modulation according to claim 30, pharmaceutical compositions according to claims 31,32, uses of the conjugates according to claims 33,34, and products according to claim 35, respectively

Inventions 32-46 (claims 1-5,9-11,16-18 and 25-35)

A conjugate comprising first and second sequences wherein the first sequence comprises a polypeptide which is capable of binding to an antigen presenting cell (APC) surface molecule selected from the group consisting of the following 14 embodiments, in respect to each invention: MHC class II, CD205, CD204, CD14, CD206, TLR, CD207, CD209, Fc gamma receptor, CD68, CD83, CD33, CD54 or BDCA-2,3,4, or is a polynucleotide which encodes therefor, and a second sequence comprises a polypeptide capable of modulating of a T cell signalling pathway according to claims 2-5, wherein it is capable of upregulating the expression or activity of Notch or a Notch ligand or a downstream component of the signalling transduction pathway, an antibody or the embodiments of Claims 10-11 or a polynucleotide sequence which encodes therefor, expression vectors comprising corresponding sequences according to claim 26 and the corresponding sequences according to claim 26, hosts according to claim 27, a method of preparing the conjugates according to claim 28, conjugates according to claim 29, methods of targeting a protein for notch signalling modulation according to claim 30, pharmaceutical compositions according to claims 31,32, uses of the conjugates according to claims 33,34, and products according to claim 35, respectively.

Invention 47 (claims 1-5,9-11,16-24 and 25-35)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A conjugate comprising first and second sequences wherein the first sequence comprises a polypeptide which is capable of binding to an antigen presenting cell (APC) surface molecule wherein the sequence is derived from superantigen according to claims 19-24, or is a polynucleotide which encodes therefor, and a second sequence comprises a polypeptide capable of modulating of a T cell signalling pathway according to claims 2-5, wherein it is capable of upregulating the expression or activity of Notch or a Notch ligand or a downstream component of the signalling transduction pathway, an antibody or the embodiments of Claims 10-11 or a polynucleotide sequence which encodes therefor, expression vectors comprising corresponding sequences according to claim 26 and the corresponding sequences according to claim 26, hosts according to claim 27, a method of preparing the conjugates according to claim 28, conjugates according to claim 29, methods of targeting a protein for notch signalling modulation according to claim 30, pharmaceutical compositions according to claims 31,32, uses of the conjugates according to claims 33,34, and products according to claim 35, respectively.

Inventions 48-62 (claims 1-5,12-15,16-18 and 25-35)

A conjugate comprising first and second sequences wherein the first sequence comprises a polypeptide which is capable of binding to an antigen presenting cell (APC) surface molecule selected from the group consisting of the following 14 embodiments, in respect to each invention: MHC class II, CD205, CD204, CD14, CD206, TLR, CD207, CD209, Fc gamma receptor, CD68, CD83, CD33, CD54 or BDCA-2,3,4, or is a polynucleotide which encodes therefor, and a second sequence comprises a polypeptide capable of modulating of a T cell signalling pathway according to claims 2-5, wherein it is capable of Notch signalling inhibition or downregulation of Notch according to claims 12-15 or a polynucleotide sequence which encodes therefor, expression vectors comprising corresponding sequences according to claim 26 and the corresponding sequences according to claim 26, hosts according to claim 27, a method of preparing the conjugates according to claim 28, conjugates according to claim 29, methods of targeting a protein for notch signalling modulation according to claim 30, pharmaceutical compositions according to claims 31,32, uses of the conjugates according to claims 33,34, and products according to claim 35, respectively.

Invention 63 (claims 1-5,12-15,16-24 and 25-35)

A conjugate comprising first and second sequences wherein the first sequence comprises a polypeptide which is capable of binding to an antigen presenting cell (APC) surface

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

molecule wherein the sequence is derived from superantigen according to claims 19-24, or is a polynucleotide which encodes therefor, and a second sequence comprises a polypeptide capable of modulating of a T cell signalling pathway according to claims 2-5, wherein it is capable of Notch signalling inhibition or downregulation of Notch according to claims 12-15 or a polynucleotide sequence which encodes therefor, expression vectors comprising corresponding sequences according to claim 26 and the corresponding sequences according to claim 26, hosts according to claim 27, a method of preparing the conjugates according to claim 28, conjugates according to claim 29, methods of targeting a protein for notch signalling modulation according to claim 30, pharmaceutical compositions according to claims 31,32, uses of the conjugates according to claims 33,34, and products according to claim 35, respectively.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/03381

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/62 C12N15/63 C07K14/47 C07K14/705 C07K19/00  
 A61K38/17 A61K39/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 20142 A (DALLMAN MARGARET JANE ;HOYNE GERALD FRANCIS (GB); IMPERIAL COLLEGE) 14 May 1998 (1998-05-14) cited in the application	1-17, 25-35
Y	abstract page 1, line 10 - line 13 page 8, line 9 - line 11 page 31; claims 15-17 see above	18-24
Y	WO 96 01650 A (KALLAND TERJE ;ABRAHMSEN LARS (SE); BJOERK PER (SE); DOHLSTEN MIKA) 25 January 1996 (1996-01-25) page 1, line 1 - line 12 page 2, line 23 - line 30 page 3, line 14 - line 16 page 3, line 22 - line 28	1-35

-/--

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

3 April 2003

Date of mailing of the international search report

09.05.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Celler, J

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/03381

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>RUBINCHIK E ET AL: "Recombinant expression and neutralizing activity of an MHC class II binding epitope of toxic shock syndrome toxin-1"</p> <p>VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB,</p> <p>vol. 18, no. 21, April 2000 (2000-04), pages 2312-2320, XP004191016</p> <p>ISSN: 0264-410X</p> <p>Introduction page 2312</p> <p>Discussion page 2319, column 1 -column 2</p> <p>---</p>	1-35
Y	<p>WO 00 36089 A (DALLMAN MARGARET JANE ;LORANTIS LTD (GB); HOYNE GERARD FRANCIS (GB) 22 June 2000 (2000-06-22)</p> <p>page 1 -page 7</p> <p>---</p>	1-35
Y	<p>WUNG J L ET AL: "Selection of phage-displayed superantigen by binding to cell-surface MHC class II."</p> <p>JOURNAL OF IMMUNOLOGICAL METHODS. NETHERLANDS 12 MAY 1997,</p> <p>vol. 204, no. 1, 12 May 1997 (1997-05-12), pages 33-41, XP002237137</p> <p>ISSN: 0022-1759</p> <p>abstract page 34, column 1 page 37, column 2, paragraph 3.3 page 39, column 2, last paragraph page 40, column 1, paragraph 2</p> <p>---</p>	1-35
Y	<p>HOYNE G F ET AL: "SERRATE-1-INDUCED NOTCH SIGNALLING REGULATES THE DECISION BETWEEN IMMUNITY AND TOLERANCE MADE BY PERIPHERAL CD4+ T CELLS"</p> <p>INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB,</p> <p>vol. 12, no. 2, 2000, pages 177-185, XP000929552</p> <p>ISSN: 0953-8178</p> <p>abstract Introductoion</p> <p>---</p>	1-35
Y	<p>WO 94 07474 A (ARTAVANIS TSAKONAS SPYRIDON ;BLAUMUELLER CHRISTINE MARIE (US); FEH) 14 April 1994 (1994-04-14)</p> <p>abstract claim 18</p> <p>-----</p>	1-35

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/03381

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9820142	A	14-05-1998	AU 736361 B2	26-07-2001
			AU 4876597 A	29-05-1998
			BG 103444 A	30-06-2000
			CZ 9901639 A3	13-10-1999
			EP 0942998 A1	22-09-1999
			GB 2353094 A ,B	14-02-2001
			WO 9820142 A1	14-05-1998
			GB 2335194 A ,B	15-09-1999
			JP 2001504331 T	03-04-2001
			KR 2000053146 A	25-08-2000
			NO 992196 A	05-07-1999
			NZ 335549 A	27-07-2001
			PL 333302 A1	22-11-1999
			TR 9901000 T2	21-07-1999
			HU 0001059 A2	28-08-2000
WO 9601650	A	25-01-1996	AT 200626 T	15-05-2001
			AU 699147 B2	26-11-1998
			AU 2994095 A	09-02-1996
			CA 2194673 A1	25-01-1996
			CN 1152877 A ,B	25-06-1997
			DE 69520739 D1	23-05-2001
			DE 69520739 T2	20-09-2001
			DK 766566 T3	13-08-2001
			EP 0766566 A1	09-04-1997
			ES 2158950 T3	16-09-2001
			FI 970100 A	10-01-1997
			GR 3036187 T3	31-10-2001
			HK 1012226 A1	04-01-2002
			HU 77257 A2	02-03-1998
			IL 114445 A	22-09-1999
			JP 11500407 T	12-01-1999
			NO 970108 A	20-02-1997
			NZ 289951 A	23-12-1998
			PL 318162 A1	26-05-1997
			PT 766566 T	28-09-2001
			RU 2183215 C2	10-06-2002
			SE 9402430 A	12-01-1996
			WO 9601650 A1	25-01-1996
			TW 413636 B	01-12-2000
			ZA 9505746 A	20-02-1996
WO 0036089	A	22-06-2000	AU 1789500 A	03-07-2000
			CA 2354147 A1	22-06-2000
			EP 1141243 A2	10-10-2001
			WO 0036089 A2	22-06-2000
			JP 2002532086 T	02-10-2002
WO 9407474	A	14-04-1994	US 5786158 A	28-07-1998
			AT 216225 T	15-05-2002
			AU 685067 B2	15-01-1998
			AU 5350394 A	26-04-1994
			CA 2145778 A1	14-04-1994
			DE 69331832 D1	23-05-2002
			DE 69331832 T2	19-12-2002
			DK 662827 T3	12-08-2002
			EP 1197220 A2	17-04-2002
			EP 1175909 A2	30-01-2002

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/03381

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9407474	A	EP 0662827 A1	19-07-1995
		ES 2174855 T3	16-11-2002
		JP 8502170 T	12-03-1996
		PT 662827 T	30-09-2002
		WO 9407474 A1	14-04-1994
		US 6083904 A	04-07-2000
<hr/>			